Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schooled On Prilosec And Zelnorm: Ironwood/Forest Aim Linzess At OTC-Dominated Market

Executive Summary

After FDA approval of Linzess, the commercial challenge of competing with over-the-counter laxatives begins. Ironwood is well-versed on the success story of proton pump inhibitors and the mixed record of withdrawn constipation/IBS drug Zelnorm when it comes to introducing a branded drug into the market.

You may also be interested in...



Keeping Track: Lower Doses Of Narcan, Linzess Approved; US FDA Receives Actemra, Ryanodex, Dextenza Submissions

The latest drug development news and highlights from our FDA Performance Tracker.

Actavis Flexes Its Commercial Muscles Ahead Of Allergan Integration

Before adding Allergan into the mix – and taking on its name – Actavis wants to show investors that it has a solid foundation as a growth pharma with strong brands in GI, CNS and women’s health.

Ironwood/Forest Hoping To Change The Conversation About Constipation

The partners began a DTC campaign to promote their constipation drug and ease the conversation between physicians and patients about the often embarrassing condition.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS054702

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel